Agios CEO Jackie Fouse
Agios CSO to depart amid layoffs as biotech looks for new drugs to license or acquire
A year and a half after ending work in oncology and three months after securing the first nod for its new “anchor product,” Agios is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
